Penumbra Inc. (NYSE: PEN) saw its stock surge 5.66% in after-hours trading on Tuesday following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year revenue guidance.

The medical device company reported Q2 revenue of $339.5 million, representing a 13.4% increase from the same period last year and surpassing the analyst consensus estimate of $327.7 million. Penumbra's adjusted earnings per share came in at $0.86, beating the expected $0.82. The company's performance was particularly strong in the U.S. market, with thrombectomy revenue growing by 22.6% and vascular thrombectomy embolization (VTE) revenue surging by 42% compared to the previous year.

Adding to investor optimism, Penumbra raised its full-year 2025 revenue guidance to a range of $1.355 billion to $1.370 billion, indicating an anticipated growth of 13% to 15% over 2024 revenue. The company also maintained its forecast for U.S. thrombectomy growth at 20% to 21% compared to 2024 levels. This positive outlook, combined with the strong quarterly performance, likely contributed to the significant after-hours stock price increase.